Gene Expression Profile and Angiogenic Markers Correlate with Response to Neoadjuvant Bevacizumab Followed by Bevacizumab plus Chemotherapy in Breast Cancer

National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Clinical Cancer Research (Impact Factor: 8.19). 10/2008; 14(18):5893-9. DOI: 10.1158/1078-0432.CCR-07-4762
Source: PubMed

ABSTRACT To identify biomarkers and gene expression profile signatures to distinguish patients with partial response (PR) from those with stable disease (SD) and progressive disease (PD).
Twenty patients with inflammatory breast cancer and one patient with locally advanced breast cancer received one cycle of bevacizumab followed by six cycles of bevacizumab plus docetaxel-doxorubicin before surgery. Baseline angiogenic/tumor markers were examined by immunohistochemistry and gene expression profiles were measured by Agilent Whole Human Genome arrays. All were assessed for clinical response.
Fourteen patients (67%, 95% confidence interval, 43-85.4%) had PR, five had SD, and two had PD. Expression of CD31 and platelet-derived growth factor receptor-beta (PDGFR-beta) in the tumor vasculature by immunohistochemistry was significantly associated with response (PR versus SD/PD; CD31 median, 33.5 versus 13.2; P = 0.0004; PDGFR-beta median, 5.9 versus 0.6; P = 0.01). Tumor VEGF-A showed a trend towards association with response (2.65 versus 0.25; P = 0.04). pVEGFR2(Y996), pVEGFR2(Y951), MVD, Ki67, apoptosis, grade, ER, HER-2/neu, and p53 were not associated with response. Twenty-six of 1,339 Gene Ontology (GO) classes at the gene transcriptional level were differentially expressed between patients with PR and SD/PD (P < 0.005). Representative significant GO classes include spindle (11 genes; P = 0.001), vascular endothelial growth factor receptor activity including PDGFR-beta (5 genes; P = 0.002), and cell motility including CD31 (80 genes; P = 0.005).
Baseline CD31, PDGFR-beta, and GO classes for vascular endothelial growth factor receptor activity and mitosis were significantly associated with response to bevacizumab followed by bevacizumab plus chemotherapy.

Download full-text


Available from: Sherry X. Yang, Jul 07, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The identification of molecular and genetic markers to predict or monitor the efficacy of bevacizumab (BV) represents a key issue in the treatment of metastatic colorectal cancer (mCRC). Plasma levels of vascular endothelial growth factor (VEGF), placental growth factor (PlGF), soluble VEGF receptor 2 (sVEGFR-2) and thrombospondin-1 (TSP-1) were assessed by ELISA assay at different time points in a cohort of 25 patients enroled in a phase II trial of GONO-FOLFOXIRI plus BV as first-line treatment of mCRC. VEGF: -2578A/C, -1498C/T, -1154A/G, -634C/G and 936C/T; and VEGFR-2: -604A/G, +1192C/T and +1719A/T, polymorphisms were assessed in a total of 54 patients. Treatment with GONO-FOLFOXIRI plus BV determined a prolonged and significant reduction in plasma free, biologically active VEGF concentration. Interestingly, VEGF concentrations remained lower than at baseline also at the time of PD. Conversely, PlGF levels increased during the treatment if compared with baseline, suggesting a possible role in tumour resistance; moreover, sVEGFR-2 increased at the time of PD, as well as TSP-1. No association of assessed polymorphisms with outcome was found. Our study suggested the possible mechanisms of resistance to combined therapy in those patients with a progressive disease to be tested in ongoing phase III randomised studies.
    British Journal of Cancer 03/2011; 104(8):1262-9. DOI:10.1038/bjc.2011.85 · 4.82 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Angiogenesis is a crucial component of tumor growth and metastasis. Targeting the vascular endothelial growth factor pathway represents therapeutic potentials for treating cancer. To date, 3 Food and Drug Administration-approved agents targeting angiogenesis have been developed, bevacizumab, sunitinib, and sorafenib. However, no validated biomarkers are available to identify those patients who are likely to benefit from antiangiogenesis therapy. Molecular biomarker research in antiangiogenesis inhibition is an actively growing field. Although current data are extremely promising, it is still uncertain which biomarker(s) can reliably predict their efficacy. With increasing numbers of inhibitors being developed, the need for biomarkers is more critical than ever. This review will focus on translational research that strives to identify molecular biomarkers (tissue, circulating and genomic) for approved antiangiogenesis therapies that can indicate benefit, resistance, and toxicity.
    The Cancer Journal 01/2011; 17(2):134-41. DOI:10.1097/PPO.0b013e318212db3c · 3.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In der neoadjuvanten und adjuvanten Therapie des Mammakarzinoms nimmt die zielgerichtete Therapie einen zunehmend größeren Stellenwert ein. Trastuzumab hat für alle Subgruppen der Patientinnen mit Her2-positivem Rezeptorstatus die Prognose wesentlich verbessert und ist derzeit die einzige zielgerichtete Substanz, die für die Adjuvanzsituation zugelassen ist. Als Tyrosinkinasehemmer wirkt sich Lapatinib ebenfalls auf den Her2-Rezeptor aus, es wird als Monosubstanz, in Kombination und Sequenz derzeit in Studien beim frühen Mammakarzinom geprüft. Bevacizumab ist die bereits am weitesten untersuchte Substanz mit Wirkung auf das VEGF-System. Die antiangiogenetische Therapie ist in der metastasierten Situation etabliert und wird derzeit in adjuvanten und neoadjuvanten Therapiedesigns geprüft. Ein Schwerpunkt der klinischen Forschung besteht darin, den Tumor nicht nur morphologisch, sondern molekularbiologisch genauer zu charakterisieren. Auf dieser Basis könnten Patientinnen für bestimmte Therapien gezielt selektiert werden, um so ihre Prognose zu verbessern. Die derzeit laufenden Phase-III-Studien werden hierzu einen wichtigen Beitrag leisten können. Specific goal-oriented therapy is increasingly gaining significance in neoadjuvant and adjuvant breast cancer therapy. For all subgroups of Her2-positive receptor patients trastuzumab provides a substantially improved prognosis and is presently recognised as the only target-oriented substance admitted to adjuvant treatment. Similar to tyrosine kinase inhibitors, lapatinib has an effect on the Her2 receptor and is currently being examined as a monosubstance both in combination and sequence as a part of studies in the early stages of breast cancer. Bevacizumab is already the most extensively examined substance with an affect on the VEGF system. Antiangiogenetic therapy is well-established in the metastasized situation and is currently being examined in adjuvant and neoadjuvant therapy designs. The existing focal point of clinical research is to precisely characterise the tumour not only morphologically but also molecular biologically. Accordingly, patients can be selected for specific therapies in order to improve the prognosis. For these reasons the current phase III studies can be expected to achieve an important contribution to breast cancer therapy.
    Der Gynäkologe 01/2009; 42(3):157-163. DOI:10.1007/s00129-008-2295-5